

Resource Summary Report

Generated by [RRID](#) on Aug 1, 2026

HMGB1 antibody - ChIP Grade

RRID:AB_444360

Type: Antibody

Proper Citation

Abcam Cat# ab18256, RRID:AB_444360

Antibody Information

URL: http://antibodyregistry.org/AB_444360

Proper Citation: Abcam Cat# ab18256, RRID:AB_444360

Target Antigen: HMGB1

Host Organism: rabbit

Clonality: polyclonal

Comments: validation status unknown, seller recommendations provided in 2012: ELISA; Immunohistochemistry; Immunoprecipitation; Western Blot; ELISA, Immunocytochemistry/Immunofluorescence, Immunohistochemistry-Fr, Immunohistochemistry-P, Immunoprecipitation, Western Blot

Antibody Name: HMGB1 antibody - ChIP Grade

Description: This polyclonal targets HMGB1

Target Organism: rat, mouse, human

Antibody ID: AB_444360

Vendor: Abcam

Catalog Number: ab18256

Record Creation Time: 20250819T204944+0000

Record Last Update: 20250819T205748+0000

Ratings and Alerts

No rating or validation information has been found for HMGB1 antibody - ChIP Grade.

No alerts have been found for HMGB1 antibody - ChIP Grade.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 39 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Mincheva G, et al. (2025) Extracellular vesicles from mesenchymal stem cells improve liver injury in rats with mild liver damage. Underlying mechanisms and role of TGF β . Life sciences, 364, 123429.

Yang H, et al. (2025) 7 I, a structurally modified sinomenine, exerts dual anti-GBM effects by inhibiting glioblastoma proliferation and inducing necroptosis which further mediates lysosomal cell death. British journal of pharmacology, 182(10), 2310.

Wang H, et al. (2025) Probiotic-mediated tumor microenvironment reprogramming with protease-sensitive interleukin-15 and photothermal therapy. Cell reports. Medicine, 6(6), 102191.

Puthdee N, et al. (2025) HMGB1-BoxA gene therapy in reversing cisplatin resistance in non-small cell lung cancer. PloS one, 20(6), e0327144.

Kim W, et al. (2025) A potent NLRP3 inhibitor effective against both MCC950-sensitive and -resistant inflammation. Cell chemical biology.

Jung SF, et al. (2025) Direct interaction of HMGB1 with SARS-CoV-2 facilitates its infection via RAGE-dependent endocytosis. iScience, 28(8), 113063.

Murakawa T, et al. (2024) AMPK regulates Bcl2-L-13-mediated mitophagy induction for cardioprotection. Cell reports, 43(12), 115001.

Lin YT, et al. (2024) Targeting acetylated high mobility group box 1 protein (HMGB1) and toll-like receptor (TLR4) interaction to alleviate hypertension and neuroinflammation in fructose-fed rats. British journal of pharmacology.

Koutsodendris N, et al. (2023) APOE4-promoted gliosis and degeneration in tauopathy are ameliorated by pharmacological inhibition of HMGB1 release. Cell reports, 42(10), 113252.

Neuwirt E, et al. (2023) Tyrosine kinase inhibitors can activate the NLRP3 inflammasome in myeloid cells through lysosomal damage and cell lysis. Science signaling, 16(768), eabh1083.

Liu X, et al. (2023) Oxylipin-PPAR γ -initiated adipocyte senescence propagates secondary senescence in the bone marrow. *Cell metabolism*, 35(4), 667.

Liu X, et al. (2023) Interventional hydrogel microsphere vaccine as an immune amplifier for activated antitumour immunity after ablation therapy. *Nature communications*, 14(1), 4106.

Zhou W, et al. (2023) Targeting the mevalonate pathway suppresses ARID1A-inactivated cancers by promoting pyroptosis. *Cancer cell*, 41(4), 740.

Lin TT, et al. (2023) Suppressing high mobility group box-1 release alleviates morphine tolerance via the adenosine 5'-monophosphate-activated protein kinase/heme oxygenase-1 pathway. *Neural regeneration research*, 18(9), 2067.

Ring NAR, et al. (2023) The p-rpS6-zone delineates wounding responses and the healing process. *Developmental cell*, 58(11), 981.

Zhu K, et al. (2023) Effects of HMGB1/RAGE/cathepsin B inhibitors on alleviating hippocampal injury by regulating microglial pyroptosis and caspase activation in neonatal hypoxic-ischemic brain damage. *Journal of neurochemistry*, 167(3), 410.

Xu SY, et al. (2023) QHRD106 ameliorates ischemic stroke injury as a long-acting tissue kallikrein preparation. *iScience*, 26(7), 107268.

Limagne E, et al. (2022) MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells. *Cancer cell*, 40(2), 136.

Yang R, et al. (2022) Posttranslational S-nitrosylation modification regulates HMGB1 secretion and promotes its proinflammatory and neurodegenerative effects. *Cell reports*, 40(11), 111330.

Kaur N, et al. (2022) Paracrine signal emanating from stressed cardiomyocytes aggravates inflammatory microenvironment in diabetic cardiomyopathy. *iScience*, 25(3), 103973.